Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study

American Journal of Psychiatry

Volumn 155, Issue 4, 1998, Pages 499-504

  Bondolfi, G ^g   Dufour, H ^g   Patris, M ^g   May, J P ^g   Billeter, U ^g   Eap, C B ^g   Baumann, P ^a   Kasas, A ^b   Juvet, P ^c   Blajev, B ^c   Meylan, C ^a   Bertschy, G ^a   Souche, A ^d   Amarilli, P ^e   Kastler, B ^e   Rogue, P ^e   Haumonte, M T ^e   Bonin, B ^f  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^b Clinique Psychiatric   (Switzerland)

^c Hopital Psychiatrique   (Switzerland)

^d Hôpital de Malévoz   (Switzerland)

^e Hôpitaux Universitaires infirmiers Emsp hcuge ch   (Switzerland)

^f UNIVERSITY HOSPITAL OF BESANÇON   (France)

^g Centre Hospitalier Universitaire ^*

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; ASTHENIA; CHRONIC DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; SEDATION; SYMPTOMATOLOGY;

EID: 0031978034     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.155.4.499     Document Type: Article

References (40)

1. Grant S, Fitton A: Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994; 48:253-273
2. Meltzer HY: An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994; 55(Sept suppl B):47-52
3. Leysen JE, Janssen PMF, Megens AAHP, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine an- tagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994; 55(May suppl):5-12
4. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
5. Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V, Klerman G: The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7:377-384
6. Pickar D, Owen RR, Litman RE, Konicki PE, Gutierrez R, Rapaport MH: Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49:345-353
7. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151:20-26
8. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151:1744-1752
9. Høyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I: Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993; 88:395-402
10. Huttunen MO, Piepponen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V: Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 1995; 91:271-277
11. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40
12. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825-835
13. Peuskens J: Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995; 166:712-726
14. Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K: Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psycho-pharmacol 1995; 15(suppl 1):45S-51S
15. Warner JP, Gledhill JA, Wakeling A: The use of risperidone in treatment-resistant schizophrenia: two case reports. Int Clin Psychopharmacol 1996; 11:65-66
16. Kay SR, Opler LA, Lindenmayer JP: Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Res 1988; 23:99-110
17. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, Md, US Department of Health, Education, and Welfare, 1976, pp 217-222
18. Chouinard G, Ross-Chouinard A, Annabel L, Jones BD: The Extrapyramidal Symptom Rating Scale (letter). Can J Neurol Sci 1980; 7:233
19. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334:1-100
20. Bondesson U, Lindstr̈m LH: Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacology (Berl) 1988; 95:472-475
21. Huang M-L, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AAI, Zylicz Z, Visscher HW, Jonkman JHG: Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54:257-268
22. Newell DJ: Intention-to-treat analysis: implications for quantitative and qualitative research. Int J Epidemiol 1992; 21:837-841
23. Glass GV, Peckham PD, Sanders JR: Consequences of failure to meet assumptions underlying the fixed effects analysis of variance and covarianee. Rev Education Res 1972; 42:237-288
24. Kleiter EF: Lehrbuch der Statistik in KMSS, Band 1/1: Niedrigkomplexe Verfahren. Weinheim, Germany, Deutscher Studien Verlag, 1990
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Statistical Assoc 1958; 53:457-481
26. Prentice RL, Mareck P: A quantitative discrepancy between censored data rank tests. Biometrics 1979; 35:861-867
27. Cohen J: Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillside, NJ, Lawrence Erlbaum Associates, 1988
28. Meylan C, Bondolfi G, Aubert AC, Baumann P: Reversible neutropenia during a cold: possible involvement of risperidone? a case report. Eur J Psychopharmacol 1995; 5:1-2
29. Fleischhacker MW, Hummer M, Kurz M, Kurzthaler I, Lieberman JA, Pollack S, Safferman AZ, Kane JM: Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry 1994; 55(Sept suppl B):78-81
30. Kurz M, Hummer M, Kurzthaler I, Oberbauer H, Fleischhacker WW: Efficacy of medium-dose clozapine for treatment-resistant schizophrenia (letter). Am J Psychiatry 1995; 152:1690-1691
31. Perry P J, Miller DD, Arndt SV, Cadoret RJ: Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148:231-235
32. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY: Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmaeol 1993; 13:383-390
33. Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, Richmond G, Carreon D, Sitanggan K, Gerber B, Telford J, Plon L, Plon H, Park L, Chang YJ, Oldroyd J, Cooper TB: Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994; 55(Sept suppl B): 133-136
34. Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, Kane JM, Lieberman JA: Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995; 152:179-182
35. VanderZwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB: Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996; 153:1579-1584
36. Van Beijsterveldt LEG, Geerts RJF, Leysen JE, Megens AAHP, Van den Eynde HMJ, Meuldermans WEG, Heykants JJP: Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berl) 1994; 114:53-62
37. Byerly MJ, DeVane CL: Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 1996; 16:177-187
38. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA: Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995; 152:827-832
39. Miller DD: The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia. Ann Clin Psychiatry 1996; 8:99-109
40. Chouinard G, Vainer JE, Bélanger MC, Turnier L, Beaudry P, Roy JY, Miller R: Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18:1 129-1141